foslevodopa/foscarbidopa vs Melevodopa/carbidopa (Sirio)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: dopamine precursor · full Parkinson's Disease pipeline
foslevodopa/foscarbidopa · Vyalev
Marketed by AbbVie
NCT04380142 · Phase 3 · completed
The trial randomized 145 participants to active treatment or an active comparator, with participants, clinicians, investigators, and outcome assessors quadruple-blinded. The primary clinical endpoint was met: least-squares mean improvement in “On” time was 2.72 hours with ABBV-951 versus 0.97 hours with oral carbidopa/levodopa, a difference of 1.75 hours (95% CI 0.46–3.05; p=0.0083).
Reported efficacy
Change From Baseline to Week 12 of the Double-Blind Treatment Period in Average Daily Normalized "On" Time Without Troublesome Dyskinesia (Baseline (Week 0) up to Week 12 of the double-blind treatment period): Change From Baseline to Week 12 of the Double-Blind Treatment Period in Average Daily Normalized "On" Time Without Troublesome Dyskinesia (Baseline (Week 0) up to Week 12 of the double-blind treatment period): ABBV-951 + Placebo for LD/CD 2.72 hours (Standard Error 0.52) vs LD/CD + Placebo for ABBV-951 0.97 hours (Standard Error 0.5) (met)
Result source: NCT04380142
Melevodopa/carbidopa (Sirio)
Marketed by Chiesi Farmaceutici
NCT00491998 · Phase 1/2 · completed
The study was randomized and double-blind, with a planned enrollment of 27 participants and a comparison with standard levodopa/carbidopa tablets. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Reported efficacy
to characterise the plasma concentrations of L-dopa after repeated doses of V1512 in fluctuating PD patients compared to standard L-dopa/carbidopa (Sinemet) over the course of the day (4 weeks): L-dopa accumulation from first to final dose across Cohorts 1/2/3: mean AUC0-t increase V1512 51%/50%/85% vs standard L-dopa/carbidopa 92%/93%/150%; mean Cmax increase V1512 30%/14%/52% vs standard 64%/23%/99%. (not_applicable)
Result source: NCT00491998
Results for Parkinson's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | foslevodopa/foscarbidopa | Melevodopa/carbidopa (Sirio) |
|---|---|---|
| OFF time, change | -2.8 vs -1.0vs LD/CDNCT04380142 | —Not reported |
| ON time without troublesome dyskinesia, change | 2.7 vs 1.0vs LD/CDNCT04380142 | —Not reported |
| UPDRS Part III, change | —Not posted · NCT04379050 | —Not reported |
| MDS-UPDRS Part II, change | -2.6 vs -1.1vs LD/CDNCT04380142 | —Not reported |
OFF time, change
- foslevodopa/foscarbidopa
- -2.8 vs -1.0vs LD/CDNCT04380142
- Melevodopa/carbidopa (Sirio)
- —Not reported
ON time without troublesome dyskinesia, change
- foslevodopa/foscarbidopa
- 2.7 vs 1.0vs LD/CDNCT04380142
- Melevodopa/carbidopa (Sirio)
- —Not reported
UPDRS Part III, change
- foslevodopa/foscarbidopa
- —Not posted · NCT04379050
- Melevodopa/carbidopa (Sirio)
- —Not reported
MDS-UPDRS Part II, change
- foslevodopa/foscarbidopa
- -2.6 vs -1.1vs LD/CDNCT04380142
- Melevodopa/carbidopa (Sirio)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. foslevodopa/foscarbidopa: 4 of 4 rows · Melevodopa/carbidopa (Sirio): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | foslevodopa/foscarbidopa |
|---|---|
| Dropout rate | — NCT04380142 · Phase 3 · Parkinson's Disease · phase 3 show 3 more results—ABBV-951 All Participants NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 42.5%high dose NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 35.9%low dose NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 |
| Discontinued due to AEs | — NCT04380142 · Phase 3 · Parkinson's Disease · phase 3 show 3 more results—ABBV-951 All Participants NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 22.1%high dose NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 17.6%low dose NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 |
| Serious AEs | 8.1% NCT04380142 · Phase 3 · Parkinson's Disease · phase 3 show 3 more results25.8%ABBV-951 All Participants NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 27.4%high dose NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 24.4%low dose NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 |
| Most frequent reported AEs | infusion site erythema 27% infusion site pain 25.7% infusion site cellulitis 17.6% NCT04380142 · Phase 3 · Parkinson's Disease · phase 3 show 3 more resultsinfusion site erythema 52% infusion site nodule 28.7% infusion site oedema 19.3% NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 high dose infusion site erythema 55.8% infusion site nodule 30.1% infusion site oedema 24.8% NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 low dose infusion site erythema 48.9% infusion site nodule 27.5% infusion site cellulitis 19.1% NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
foslevodopa/foscarbidopa
show 17 more results
show 17 more results
show 17 more results
show 29 more results
+ 6 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: foslevodopa/foscarbidopa's landscape · Melevodopa/carbidopa (Sirio)'s landscape